Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A long-term, open-label study of the efficacy and tolerability of policosanol in patients with high global coronary risk
Autore:
Castano, G; Mas, R; Fernandez, JC; Lopez, LE; Fernandez, L;
Indirizzi:
Natl Ctr Sci Res, Havana 6880, Cuba Natl Ctr Sci Res Havana Cuba 6880Natl Ctr Sci Res, Havana 6880, Cuba Med Surg Res Ctr, Havana, Cuba Med Surg Res Ctr Havana CubaMed Surg Res Ctr, Havana, Cuba
Titolo Testata:
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
fascicolo: 7, volume: 60, anno: 1999,
pagine: 379 - 391
SICI:
0011-393X(199907)60:7<379:ALOSOT>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
SPRAGUE-DAWLEY RATS; II HYPERCHOLESTEROLEMIA; PLATELET-AGGREGATION; DENSITY LIPOPROTEIN; HEALTHY-VOLUNTEERS; ELDERLY PATIENTS; LIPID PROFILE; HEART-DISEASE; CHOLESTEROL; SAFETY;
Keywords:
policosanol; high coronary risk; long-term study; cholesterol-lowering drug;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
49
Recensione:
Indirizzi per estratti:
Indirizzo: Mas, R Natl Ctr Sci Res, POB 6880, Havana 6880, Cuba Natl Ctr Sci Res POB 6880 Havana Cuba 6880 6880, Havana 6880, Cuba
Citazione:
G. Castano et al., "A long-term, open-label study of the efficacy and tolerability of policosanol in patients with high global coronary risk", CURR THER R, 60(7), 1999, pp. 379-391

Abstract

In the present long-term, open-label study, the effects of policosanol (20mg/d) were investigated in the treatment of type II hypercholesterolemia in patients with high global coronary risk. After dietary stabilization during a 5-week baseline period, 68 patients took policosanol 20 mg once daily with the evening meal for 12 months. All of the patients had nonlipid coronary risk factors, such as a family history of coronary disease (88.2%), hypertension (70.6%), previous coronary events (60.3%), and severe hypercholesterolemia (total cholesterol >7.8 mmol/L) (60.3%). After 2 months of treatment with policosanol, low-density lipoprotein cholesterol (LDL-C) and totalcholesterol decreased significantly (P < 0.00001) by 24.7% and 15.9%, respectively, and high-density lipoprortein cholesterol (HDLC) increased significantly (P < 0.0001) by 31.1%. The ratios of total cholesterol to HDL-C andLDL-C to HDL-C decreased significantly (P < 0.00001) by 29.3% and 37.8%, respectively. These effects continued to increase, although moderately, during the 12-month follow-up. At the end of the study, reductions were noted in total cholesterol (30.0%), LDL-C (44.8%), total cholesterol to HDL-C ratio (54.1%), and LDL-C to HDL-C ratio (62.7%), whereas HDL-C increased by 68.5%. Triglycerides, which decreased significantly from 4 until 12 months, were 21.2% lower at 12 months than at baseline. Of 59 patients who completed the study, 56 (94.9%) had reductions in LDL-C greater than or equal to 15% at study completion. The treatment was well tolerated; no drug-related clinical or biochemical adverse effects (AEs) were detected. None of the patients withdrew from the study because of AEs, and only 4 patients reported mild AEs during the study. Results of the present study show that policosanol 20 mg once daily for 1 year was effective and well tolerated in patients with type II hypercholesterolemia and high global coronary risk.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/10/20 alle ore 03:10:46